Novartis finds buyer to save 270 jobs at German plant

Novartis ($NVS) was all set to close the door on a Sandoz intermediates plant in Germany last year, thanks to some hefty competition from Asia. But now, the Swiss pharma giant has a buyer willing to take the plant--and salvage the 270 jobs that would have been chopped. More from FiercePharmaManufacturing

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.